Laboratorios Farmaceuticos Rovi, SA (ES:ROVI)
BME:ROVI
Earnings Data
Report Date
May 13, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
0.35Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Overall the call conveyed a constructive but cautious outlook. Profitability, margins, cash generation and specialty pharma (notably Okedi and enoxaparin) showed clear strength, ROVI secured strategic assets (Phoenix acquisition, Roche collaboration) and advanced key pipeline milestones (positive Phase I results and IND submission). Offsetting these positives were a 3% operating revenue decline in 2025 driven by a 20% drop in CDMO sales, near-term headwinds in the heparin business from inventory and pricing pressure, increased near-term R&D intensity, and timing uncertainty around Phoenix/BMS-related revenue. Management reiterated 2026 revenue guidance (high single-digit to low double-digit growth) and emphasized investments to capture future CDMO demand, supporting a positive medium‑term outlook despite short-term execution and market risks.Company Guidance
Strong Profitability and Margin Expansion
EBITDA increased 4% to EUR 216.2 million and EBITDA margin expanded by 1.9 percentage points to 29.1% in 2025. Gross profit rose 3% to EUR 494.7 million and gross margin improved 3.9 percentage points to 66.5% (64.8% ex other income). EBIT increased 4% to EUR 185.8 million (EBIT margin 25%), and net profit increased 3% to EUR 140.4 million.
Robust Cash Generation and Dividend Policy
Operating cash flow increased 35% to EUR 187.1 million and free cash flow rose 57% to EUR 120 million in 2025. Net debt remained modest at EUR 21.9 million as of 31 Dec 2025, and the Board will propose a dividend distribution of over EUR 49 million (~EUR 0.9594 per share), ~35% of consolidated net profit.
Specialty Pharma Growth
Specialty pharmaceutical revenue increased 11% to EUR 473.9 million in 2025. Prescription-based product sales rose 11% to EUR 414.1 million. Enoxaparin sales grew 9% (sales of EUR 157.7 million), bemiparin +4% (with Q4 up 53% vs Q3), Neparvis +10%, and contrast imaging & hospital products +11%.
Breakout Performance for Okedi
Okedi sales reached EUR 56.7 million in 2025, a 97% increase versus 2024 (and an 84% increase versus Q4 2024), demonstrating strong commercial traction for ROVI's ISM-based product.
Strategic M&A and Partnerships Strengthening CDMO Footprint
Acquisition of injectable manufacturing site in Phoenix (ROIS Phoenix) integrated into the network; signed a drug manufacturing agreement tied to the transaction with an initial 5-year term including minimum annual payments of USD 50 million. Announced collaboration with Roche for manufacture of a new medicine and continuing partnership activity with Moderna.
R&D and Pipeline Progress
Positive Phase I results in 2025 for both Letrozole SIE and Risperidone QUAR. IND for Letrozole SIE submitted to U.S. FDA in Nov 2025; recruitment expected to begin in Q2 2026. Both programs advancing toward pivotal Phase III development and represent meaningful long-term value for the ISM platform.
Technology and Grant Recognition
ROVI collected the full EUR 36.3 million CDTI aid for the LAISOLID project (Jan 2023–Aug 2026) and acquired a majority stake in Cells IA Technologies to advance AI-assisted diagnostics capabilities.
CapEx Investments to Support Growth
Total 2025 CapEx of EUR 67.8 million (EUR 46.2 million investment CapEx on facilities including new filling lines, ROIS Phoenix integration, Glicopepton JV and ISM industrialization; EUR 21.6 million maintenance/other) positioning capacity expansion and vertical integration.
2026 Revenue Guidance Reaffirmed
Company reaffirms 2026 operating revenue guidance: expected growth of high single-digit to low double-digit percentages versus 2025, reflecting expected contributions from CDMO agreements (including potential BMS-related revenue) and continued specialty pharma momentum.
Laboratorios Farmaceuticos Rovi (ES:ROVI) Earnings, Revenues Date & History
ES:ROVI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ES:ROVI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 25, 2026 | €78.20 | €82.05 | +4.92% |
Nov 06, 2025 | €57.65 | €55.00 | -4.60% |
Jul 24, 2025 | €54.40 | €57.15 | +5.06% |
May 08, 2025 | €50.65 | €51.98 | +2.63% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Laboratorios Farmaceuticos Rovi, SA (ES:ROVI) report earnings?
Laboratorios Farmaceuticos Rovi, SA (ES:ROVI) is schdueled to report earning on May 13, 2026, TBA (Confirmed).
What is Laboratorios Farmaceuticos Rovi, SA (ES:ROVI) earnings time?
Laboratorios Farmaceuticos Rovi, SA (ES:ROVI) earnings time is at May 13, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Laboratorios Farmaceuticos Rovi, SA stock?
The P/E ratio of Laboratorios Farmaceuticos Rovi is N/A.
What is ES:ROVI EPS forecast?
Currently, no data Available